Investigational drug · Phase 3
MTBVAC
Also called: BBV169
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Tuberculosis, Tuberculosis (TB).
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "MTBVAC"
First trial start
2022
Oct 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MTBVAC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
- Tuberculosis (TB)
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "MTBVAC" as an intervention, largest first.
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaPivotal-lookingRecruiting
Biofabri, S.LIndustry
NCT04975178 · 7,120 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 2029
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.Pivotal-lookingActive, not recruiting
International AIDS Vaccine InitiativeResearch network
NCT06272812 · 5,531 participants · Start Feb 19, 2025 · Primary completion Dec 31, 2028
Drug: MTBVAC; Placebo · For: Tuberculosis (TB)
Sites: Kisumu, Kenya; Nairobi, Kenya; Bloemfontein, South Africa · 16 sites in all
- Evaluating the Safety and Immunogenicity of MTBVACPivotal-lookingRecruiting
HIV Vaccine Trials NetworkResearch network
NCT05947890 · 276 participants (planned) · Start Jan 30, 2024 · Primary completion Nov 2027
Drug: MTBVAC; BCG · For: HIV I Infection; Tuberculosis
Sites: Johannesburg, South Africa; Westdene, South Africa; Durban, South Africa · 16 sites in all
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)Pivotal-lookingActive, not recruiting
Bharat Biotech International LimitedIndustry
NCT06997367 · 164 participants (planned) · Start Mar 27, 2025 · Primary completion Sep 1, 2025
Drug: MTBVAC; BCG Sii · For: Tuberculosis (TB)
Sites: Delhi, India; New Delhi, India
- MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South AfricaPivotal-lookingCompleted
International AIDS Vaccine InitiativeResearch network
NCT02933281 · 144 participants · Start May 14, 2018 · Primary completion Sep 5, 2021
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
Biofabri, S.LIndustry
NCT03536117 · 99 participants · Start Feb 12, 2019 · Primary completion May 17, 2022
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
Biofabri, S.LIndustry
NCT02729571 · 54 participants · Start Sep 2015 · Primary completion Sep 2016
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
Biofabri, S.LIndustry
NCT02013245 · 36 participants · Start Jan 2013 · Primary completion Jun 2014
Drug: MTBVAC live vaccine; Commercially available BCG live vaccine · For: Tuberculosis; Healthy
Sites: Lausanne, Switzerland
Bharat Biotech International LimitedIndustry
NCT06438978 · 30 participants · Start Jan 19, 2024 · Primary completion Jan 29, 2024
Drug: Tuberculosis Vaccine · For: Tuberculosis
Sites: Hyderabad, India
Newest research
PubMed records naming it or its code names, newest first.
- Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access.
da Costa C, Marais BJ, Goletti D, et al. · Lancet Microbe 2026
- BCG at 100: The Paradox of an Indispensable Vaccine.
Vashishtha VM · Indian Pediatr 2026
- Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.
He Y, Xie X, He S, et al. · Front Immunol 2026
- TB vaccine development: monitoring international patent filings to anticipate access challenges.
Pignataro MF, Scopel CT, Bacigalupo ML, et al. · Front Public Health 2025
- Overcoming Treatment Challenges in HIV-Associated Mycobacterial Diseases: New Therapeutic Frontiers.
Nikjeh O, Rejali S, Sasaninia K, et al. · Int J Mol Sci 2025
- Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.
Luabeya AKK, Rozot V, Imbratta C, et al. · Lancet Glob Health 2025
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.